Breast Cancer
📧 Sign up to get email alerts when something new happens for Breast Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-04-24Clinical Trial Update: Cancer-related Fatigue in Patients With Breast Cancer Treatment With Zhengyuan Capsules [Phase 4]
Phase 4 trial evaluating Zhengyuan capsules for cancer-related fatigue in breast cancer patients; status not yet recruiting.
-
CLINICAL_TRIALS trial_result · 2024-04-23Clinical Trial Update: A Multicenter, Double-blind, Randomized, Parallel-group, Phase III Study of the Efficacy and Safety of QL1701 Plus Docetaxel Versus Herceptin® Plus Docetaxel as First Line Therapy in Patients With HER2-positive Metastatic Breast Cancer [Phase 3]
Phase III trial comparing QL1701 plus docetaxel to Herceptin plus docetaxel as first-line therapy for HER2-positive metastatic breast cancer…
-
CLINICAL_TRIALS trial_result · 2024-04-23Clinical Trial Update: Higher Dose Preoperative taMOxifen in Premenopausal bREast Cancer Patients [Phase 2]
Phase 2 trial update evaluating a higher dose of preoperative taMOxifen in premenopausal women with hormone receptor-positive breast cancer.
-
CLINICAL_TRIALS trial_result · 2024-04-23Clinical Trial Update: Phase II Study of Tetrathiomolybdate (TM) in Patients With Breast Cancer [Phase 2]
A Phase II study of tetrathiomolybdate in breast cancer was terminated; results from the trial have been posted on ClinicalTrials.gov.
-
CLINICAL_TRIALS trial_result · 2024-04-19Clinical Trial Update: Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive and Estrogen Receptor/Progesterone Receptor Negative Breast Cancer to Evaluate the Efficiency and Safety of Treatment With Trastuzumab Plus (+) QL1209/Pertuzumab + Docetaxel. [Phase 3]
Phase 3 trial evaluating trastuzumab plus pertuzumab (QL1209) with docetaxel in early-stage or locally advanced HER2-positive, ER/PR-negativ…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2024-04-18Clinical Trial Update: The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer [Phase 2]
Phase 2 AVIATOR study evaluates trastuzumab and vinorelbine with either avelumab or utomilumab in advanced HER2-positive breast cancer; resu…
-
CLINICAL_TRIALS trial_result · 2024-04-18Clinical Trial Update: Study of Palbociclib and Trastuzumab With Endocrine Therapy in HER2-positive Metastatic Breast Cancer [Phase 2]
Phase 2 trial evaluating palbociclib and trastuzumab with endocrine therapy in HER2-positive metastatic breast cancer has completed enrollme…
-
FDA approval · 2024-04-15FDA Approved: CAPECITABINE — Supplemental Application (Cipla USA Inc.)
The FDA approved Cipla USA Inc.'s supplemental application for Capecitabine, updating regulatory status for this cancer drug. The action lik…
-
CLINICAL_TRIALS trial_result · 2024-04-10Clinical Trial Update: Chemotherapy Omission in ER+/HER2- Breast Cancer With 1-3 Positive Lymph Nodes Receiving Extended Adjuvant Abemaciclib [Phase 3]
Phase 3 trial investigating chemotherapy omission with extended adjuvant abemaciclib in ER+/HER2- breast cancer with 1-3 positive lymph node…
-
CLINICAL_TRIALS trial_result · 2024-04-08Clinical Trial Update: Ultrasound in Detecting Taxane-Induced Neuropathy in Patients With Breast Cancer [NA]
Clinical trial update evaluating ultrasound for detecting taxane-induced neuropathy in breast cancer patients has completed with results pos…
-
CLINICAL_TRIALS trial_result · 2024-04-05Clinical Trial Update: Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer [Phase 2]
A Phase 2 trial evaluated two ribociclib dose levels in combination with aromatase inhibitors for HR-positive, HER2-negative advanced breast…
-
FDA approval · 2024-04-05FDA Approved: ERIBULIN MESYLATE — Original Application (Gland Pharma Limited)
FDA approved an original (generic) application for Eribulin Mesylate from Gland Pharma Limited, authorizing the generic version of the produ…
-
CLINICAL_TRIALS trial_result · 2024-04-04Clinical Trial Update: Radiologic Evaluation and Breast Density (READ) [NA]
Completed clinical trial with radiologic evaluation and breast density data in breast cancer patients; results posted.
-
CLINICAL_TRIALS trial_result · 2024-04-04Clinical Trial Update: Evaluate the Effectiveness and Toxicity of Adjuvant Ultra-hypofractionated Radiotherapy for Breast Cancer [Phase 2]
A Phase 2 trial assessing the effectiveness and toxicity of adjuvant ultra-hypofractionated radiotherapy in female breast cancer.
-
CLINICAL_TRIALS trial_result · 2024-04-02Clinical Trial Update: Potential Protective Role of SGLT-2 Inhibitors for Chemotherapy-induced Cardiotoxicity [Phase 2]
Phase 2 clinical trial exploring a potential protective role of SGLT-2 inhibitors against chemotherapy-induced cardiotoxicity in breast canc…
-
CLINICAL_TRIALS trial_result · 2024-03-29Clinical Trial Update: Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer, TRAIN-2 [Phase 3]
Phase 3 trial update for neoadjuvant chemotherapy in HER2-positive breast cancer (TRAIN-2) is active but not recruiting.
-
CLINICAL_TRIALS trial_result · 2024-03-29Clinical Trial Update: Dose Escalation Study MORAb-066 Targeting Tissue Factor (TF)-Expressing Malignancies Including Breast, Pancreatic, Colorectal, NSCLC [Phase 1]
Phase 1 dose-escalation study of MORAb-066 targeting tissue factor-expressing malignancies, including breast, pancreatic, colorectal, and no…
-
CLINICAL_TRIALS trial_result · 2024-03-27Clinical Trial Update: Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments [Phase 2]
A Phase 2 study assessing alpelisib with either fulvestrant or letrozole in PIK3CA-mutant, HR+, HER2-negative advanced breast cancer that pr…
-
CLINICAL_TRIALS trial_result · 2024-03-27Clinical Trial Update: Effects of Exemestane on Bone Strength
A completed clinical trial assessing the effects of exemestane on bone strength in patients with osteoporosis and breast cancer; results pos…
-
CLINICAL_TRIALS trial_result · 2024-03-25Clinical Trial Update: HCQ+ADC vs ADC in the Treatment of Advanced Breast Cancer [Phase 1, Phase 2]
Clinical trial update for HCQ+ADC vs ADC in advanced/metastatic breast cancer across Phase 1 and Phase 2.
-
CLINICAL_TRIALS trial_result · 2024-03-22Clinical Trial Update: PAlbociclib Plus Tamoxifen for the Treatment of Hormone Receptor-positive, HER2-negative Advanced Breast Cancer Women - Asian studY [Phase 3]
A Phase 3 trial evaluating palbociclib combined with tamoxifen for HR-positive, HER2-negative advanced breast cancer in Asian women is repor…
-
CLINICAL_TRIALS trial_result · 2024-03-22Clinical Trial Update: A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer [Phase 1]
An early-phase study evaluating H3B-6545 in combination with palbociclib for advanced or metastatic estrogen receptor-positive, HER2-negativ…
-
FDA approval · 2024-03-21FDA Approved: FULVESTRANT — Supplemental Application (Amneal Pharmaceuticals LLC)
The FDA approved a supplemental application from Amneal Pharmaceuticals LLC for Fulvestrant (generic), under ANDA210044, indicating approval…
-
CLINICAL_TRIALS trial_result · 2024-03-21Clinical Trial Update: Electroacupuncture Plus Antiemetic Therapy for Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer [Phase 3]
Phase 3 clinical trial investigating electroacupuncture plus a four-drug antiemetic regimen (including olanzapine) for chemotherapy-induced …
-
CLINICAL_TRIALS trial_result · 2024-03-20Clinical Trial Update: A Study of TAS-120 in Patients With Advanced Solid Tumors [Phase 1, Phase 2]
A Phase 1/2 study of futibatinib (TAS-120) in patients with advanced solid tumors, including cholangiocarcinoma, urothelial carcinoma, breas…